Skip to main content
Clinical Trials/CTRI/2018/11/016425
CTRI/2018/11/016425
Not Yet Recruiting
Phase 3

A Randomized Controlled Trial comparing the efficacy and safety of Olanzapine and Haloperidol , and its assessment with homocysteine in schizophrenia patients - OLHALOHOMSCHIZO

VENKATA AKSHEENA VARAHI VEDAM0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
VENKATA AKSHEENA VARAHI VEDAM
Status
Not Yet Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
VENKATA AKSHEENA VARAHI VEDAM

Eligibility Criteria

Inclusion Criteria

  • A newly diagnosed schizophrenia acording to DSM\-V criteria

Exclusion Criteria

  • Known allergic to Olanzapine or Haloperidol
  • \-Unstable patients unable to give consent for the study
  • \-Liver failure and kidney failure patients
  • \-Pregnant women and lactating mothers
  • \-Subject who is currently enrolled in another investigational drug study

Outcomes

Primary Outcomes

Not specified

Similar Trials